Your browser doesn't support javascript.
loading
Ubiquitin ligase RNF125 targets PD-L1 for ubiquitination and degradation.
Wei, Meng; Mo, Yunhai; Liu, Jialong; Zhai, Jingtong; Li, Huilong; Xu, Yixin; Peng, Yumeng; Tang, Zhihong; Wei, Tao; Yang, Xiaopan; Huang, Linfei; Shao, Xiao; Li, Jingfei; Zhou, Li; Zhong, Hui; Wei, Congwen; Xie, Qiaosheng; Min, Min; Wu, Feixiang.
Affiliation
  • Wei M; Department of Hepatobiliary Surgery, Affiliated Tumor Hospital of Guangxi Medical University, Nanning, China.
  • Mo Y; Key Laboratory of High-Incidence-Tumor Prevention and Treatment (Guangxi Medical University), Ministry of Education, Nanning, China.
  • Liu J; Department of Hepatobiliary Surgery, Affiliated Tumor Hospital of Guangxi Medical University, Nanning, China.
  • Zhai J; Key Laboratory of High-Incidence-Tumor Prevention and Treatment (Guangxi Medical University), Ministry of Education, Nanning, China.
  • Li H; Department of Genetic Engineering, Beijing Institute of Biotechnology, Beijing, China.
  • Xu Y; Department of Medical Oncology and State Key Laboratory of Molecular Oncology, National Cancer Center/ Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
  • Peng Y; Department of Hepatobiliary Surgery, Affiliated Tumor Hospital of Guangxi Medical University, Nanning, China.
  • Tang Z; Key Laboratory of High-Incidence-Tumor Prevention and Treatment (Guangxi Medical University), Ministry of Education, Nanning, China.
  • Wei T; Department of Hepatobiliary Surgery, Affiliated Tumor Hospital of Guangxi Medical University, Nanning, China.
  • Yang X; Key Laboratory of High-Incidence-Tumor Prevention and Treatment (Guangxi Medical University), Ministry of Education, Nanning, China.
  • Huang L; Department of Hepatobiliary Surgery, Affiliated Tumor Hospital of Guangxi Medical University, Nanning, China.
  • Shao X; Key Laboratory of High-Incidence-Tumor Prevention and Treatment (Guangxi Medical University), Ministry of Education, Nanning, China.
  • Li J; Department of Hepatobiliary Surgery, Affiliated Tumor Hospital of Guangxi Medical University, Nanning, China.
  • Zhou L; Key Laboratory of High-Incidence-Tumor Prevention and Treatment (Guangxi Medical University), Ministry of Education, Nanning, China.
  • Zhong H; Department of Hepatobiliary Surgery, Affiliated Tumor Hospital of Guangxi Medical University, Nanning, China.
  • Wei C; Key Laboratory of High-Incidence-Tumor Prevention and Treatment (Guangxi Medical University), Ministry of Education, Nanning, China.
  • Xie Q; Department of Genetic Engineering, Beijing Institute of Biotechnology, Beijing, China.
  • Min M; Department of Genetic Engineering, Beijing Institute of Biotechnology, Beijing, China.
  • Wu F; Department of Gastroenterology, First Medical Center of Chinese People's Liberation Army General Hospital, Beijing, China.
Front Oncol ; 12: 835603, 2022.
Article in En | MEDLINE | ID: mdl-35965501
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Prognostic_studies Language: En Journal: Front Oncol Year: 2022 Document type: Article Affiliation country: Country of publication:
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Prognostic_studies Language: En Journal: Front Oncol Year: 2022 Document type: Article Affiliation country: Country of publication: